↓ Skip to main content

Dove Medical Press

Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy

Overview of attention for article published in Cancer Management and Research, February 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
4 X users

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
41 Mendeley
Title
Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy
Published in
Cancer Management and Research, February 2018
DOI 10.2147/cmar.s149983
Pubmed ID
Authors

Winnie Yeo, Frankie KF Mo, Elizabeth Pang, Joyce JS Suen, Jane Koh, Claudia HW Yip, Christopher CH Yip, Leung Li, Herbert HF Loong, Giok S Liem

Abstract

Understanding of quality of life (QoL) of young Chinese breast cancer patients after adjuvant cytotoxic chemotherapy is limited. This study aims to assess the QoL of premenopausal Chinese breast cancer women after receiving adjuvant chemotherapy. Eligibility criteria included stage I-III breast cancer, premenopausal and age ≤45 years at cancer diagnosis and having received adjuvant chemotherapy within 3-10 years before entry to the present study. Patients' background demographics at the time of breast cancer diagnosis, together with tumor characteristics and anticancer treatments, were collected. At the time of study entry, the menopausal status based on menstrual history, body mass index, and QoL (assessed using Functional Assessment of Cancer Therapy-Breast +4) were recorded. Two hundred and eighty patients were recruited. Ninety-five patients (33.9%) underwent breast-conserving surgery, and nearly all (98.6%) underwent axillary dissection. For adjuvant therapies, 249 patients (88.9%) received anthracycline-containing chemotherapy and 79 (28.2%) received taxane-containing chemotherapy, while 68 (24.3%) received both. One hundred and eighty six patients (66.4%) received adjuvant radiotherapy, and 214 (76.4%) received adjuvant tamoxifen. The median time from breast cancer diagnosis to study entry was 5.01 years. QoL assessment at study entry revealed that older patients had worse social well-being (SWB; mean scores for age ≤40, 41-45, 46-50 and >50 years were 22.0, 19.3, 19.1 and 18.1, respectively, P=0.0442). Patients who underwent axillary dissection had worse scores for breast cancer sub-scale (BCS; mean score 22.2 vs. 28.3, P=0.0212). Patients who underwent taxane-containing chemotherapy had worse scores for arm subscale (mean score 13.8 vs. 15.3, P=0.0053). At a median follow-up of 5 years post-diagnosis, patients who were younger had fewer disturbances in their SWB. Patients who had axillary dissection had worse BCS scores, while those who received taxane had worse scores for arm subscale. Further studies are warranted for breast-specific QoL to address the specific issues encountered by breast cancer patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 17%
Researcher 4 10%
Student > Bachelor 3 7%
Student > Postgraduate 3 7%
Student > Ph. D. Student 3 7%
Other 6 15%
Unknown 15 37%
Readers by discipline Count As %
Medicine and Dentistry 13 32%
Nursing and Health Professions 4 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Decision Sciences 1 2%
Arts and Humanities 1 2%
Other 2 5%
Unknown 17 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2018.
All research outputs
#13,065,845
of 23,023,224 outputs
Outputs from Cancer Management and Research
#438
of 2,016 outputs
Outputs of similar age
#206,919
of 440,124 outputs
Outputs of similar age from Cancer Management and Research
#17
of 43 outputs
Altmetric has tracked 23,023,224 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,016 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,124 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.